**JB Chemicals & Pharmaceuticals Reports 21% Increase in Q3 Profit**
New Delhi, Feb 4 (PTI) – JB Chemicals & Pharmaceuticals announced a 21% rise in profit after tax, reaching ₹162 crore for the third quarter ending December 2024, attributed to robust sales growth in both domestic and international markets. In the same quarter of the previous fiscal year, the company recorded a profit after tax (PAT) of ₹134 crore. Revenue for the third quarter surged to ₹963 crore, up from ₹845 crore in the corresponding period last year, according to the company’s statement.
CEO Nikhil Chopra highlighted that the company has maintained consistent growth over recent years, even amid a fluctuating macroeconomic landscape. This success is largely due to its diverse business mix and market focus, particularly on India branded formulations, contract development and manufacturing organization (CDMO), and select international markets, which align with the company’s strengths while minimizing exposure to regions with potential trade or economic volatility.
Chopra also noted that the advancement of various new projects within the CDMO sector is expected to contribute positively to growth figures in the near to medium term. The company has a promising pipeline for future product commercialization opportunities in international markets, which will support ongoing growth.
Additionally, the board has approved an interim dividend of ₹8.5 per share with a face value of Re 1 for the financial year 2024-25, set to be credited on February 21, 2025. On the stock market, shares of JB Chemicals & Pharmaceuticals closed 1.59% higher at ₹1,741.35 each on the BSE.
